What is the 13F Pro Quality Score for LFST?

13F Pro ranks LifeStance Health Group, Inc. (LFST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LFST's current score at https://13fpro.ai/research/LFST (free sign-up required for the full ranking).

Which hedge funds own the most LFST stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LFST include TPG GP A,, FMR, SUMMIT PARTNERS L P. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LFST as soon as new 13F filings post.

Where does 13F Pro source LFST data?

All LifeStance Health Group, Inc. fundamentals and ownership data come directly from SEC EDGAR. LifeStance Health Group, Inc. files with the SEC under CIK 1845257. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LFST in?

LifeStance Health Group, Inc. (LFST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LFST research updated on 13F Pro?

LFST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LifeStance Health Group, Inc.(LFST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1845257 LFST stock profile & AI dashboard →

13F Pro Quality Score

53.7/100

Rank #1,265 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

76.3/100

Profitability

57.0/100

Balance Sheet

39.8/100

Earnings Quality

30.0/100

Free Cash Flow

53.5/100

Institutional Flow

36.8/100

Revenue Scale

56.6/100

Dilution Risk

25.2/100

LFST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LifeStance Health Group, Inc. (LFST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFST at 53.7/100 on a 32-signal composite quality model, placing it at rank #1,265 of 2,879 stocks — the top half of the AI-ranked universe. LFST scores in the top quartile across revenue growth (76.3). Areas of concern include earnings quality (30.0) and institutional flow (36.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LifeStance Health Group, Inc. reports quarterly revenue of $403.5M, net income of $14.2M, an operating margin of 5.5%. Top institutional holders of LFST by reported 13-F value include TPG GP A,, FMR, SUMMIT PARTNERS L P, based on the most recent SEC filings. LFST trades on the Nasdaq exchange and files with the SEC under CIK 1845257. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LifeStance Health Group, Inc. directly from SEC EDGAR. LifeStance Health Group, Inc.'s 13F Pro composite quality score has ranged between 8 and 68 since 2022, currently 53.7 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q1 2026

$403.5M

Net Income

Q1 2026

$14.2M

Free Cash Flow

Q1 2026

$22.3M

Operating Margin

Q1 2026

5.5%

ROIC

Q1 2026

1.3%

D/E Ratio

Q1 2026

0.20

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+13.9% YoY

$1.42BFY 2025

FY18 —FY19 $212.5MFY24 $1.25BFY25 $1.42B

Net Income

+116.8% YoY

$9.7MFY 2025

FY18 —FY19 $5.7MFY24 $-57.4MFY25 $9.7M

Operating Income

+176.4% YoY

$24.1MFY 2025

FY18 —FY19 $15.2MFY24 $-31.6MFY25 $24.1M

Total Assets

+4.0% YoY

$2.20BFY 2025

FY18 —FY19 —FY24 $2.12BFY25 $2.20B

Total Debt

+0.0% YoY

$297.3MFY 2025

FY18 —FY19 —FY24 $297.3MFY25 $297.3M

Op. Cash Flow

+36.3% YoY

$146.2MFY 2025

FY18 —FY19 $17.0MFY24 $107.3MFY25 $146.2M

Metric	FY 2025	FY 2024	FY 2019	FY 2018
Revenue	$1.42B +13.9%	$1.25B +488.6%	$212.5M	—
Net Income	$9.7M +116.8%	$-57.4M -1113.3%	$5.7M	—
Operating Income	$24.1M +176.4%	$-31.6M -307.4%	$15.2M	—
Total Assets	$2.20B +4.0%	$2.12B	—	—
Total Debt	$297.3M +0.0%	$297.3M	—	—
Operating Cash Flow	$146.2M +36.3%	$107.3M +529.2%	$17.0M	—

AI Insight: LFST Financial Trends

LifeStance achieved profitability with net income turning positive to $14M in Q1 2026 from $-23M losses in Q2 2024.

• Revenue grew consistently from $312M in Q2 2024 to $403M in Q1 2026, representing 29% growth.

• Operating income improved dramatically from $-16M in Q2 2024 to $22M in Q1 2026.

• Net income turned positive in Q4 2025 at $12M and continued to $14M in Q1 2026.

• Total debt remained stable around $297M while equity grew from $1,430M to $1,477M.

⚠ Operating cash flow turned negative to $-3M in Q1 2025 despite improving profitability trends.

⚠ Equity declined from $1,521M in Q4 2025 to $1,477M in Q1 2026 despite positive earnings.

AI Insight: LFST Ratio Trends

LifeStance achieved sustained profitability turnaround with operating margin expanding from -5.1% in Q2 2024 to 5.5% in Q1 2026.

• Operating margin surged from -5.1% in Q2 2024 to 5.5% in Q1 2026, marking seven consecutive quarters of improvement.

• ROIC turned positive in Q4 2024 at 0.2% and accelerated to 5.0% by Q1 2026.

• Net profit margin shifted from -7.4% losses in Q2 2024 to 3.5% profitability in Q1 2026.

• Debt-to-equity ratio remained stable at 0.20 throughout the turnaround period, indicating disciplined capital structure.

⚠ TTM operating margin of 3.0% lags the Q1 2026 quarterly rate of 5.5%, suggesting recent acceleration may face sustainability questions.

⚠ Q2 2025 saw temporary margin compression with operating margin falling to -0.9% before rebounding strongly.

Get alerted when LFST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LifeStance Health Group, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LFST

TPG GP A, LLC
$892.0M140,026,557 sh
FMR LLC
$373.8M58,685,480 sh
SUMMIT PARTNERS L P
$186.1M29,209,776 sh
BlackRock, Inc.
$115.5M18,134,951 sh
DIMENSIONAL FUND ADVISORS LP
$66.0M10,367,680 sh
JENNISON ASSOCIATES LLC
$65.2M10,228,801 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$61.7M9,682,305 sh
VANGUARD CAPITAL MANAGEMENT LLC
$50.4M7,908,159 sh
Silversmith Partners I GP, LLC
$39.2M6,157,127 sh
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$38.8M6,092,223 sh

Fund	Value	Shares
TPG GP A, LLC	$892.0M	140,026,557
FMR LLC	$373.8M	58,685,480
SUMMIT PARTNERS L P	$186.1M	29,209,776
BlackRock, Inc.	$115.5M	18,134,951
DIMENSIONAL FUND ADVISORS LP	$66.0M	10,367,680
JENNISON ASSOCIATES LLC	$65.2M	10,228,801
VANGUARD PORTFOLIO MANAGEMENT LLC	$61.7M	9,682,305
VANGUARD CAPITAL MANAGEMENT LLC	$50.4M	7,908,159
Silversmith Partners I GP, LLC	$39.2M	6,157,127
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME	$38.8M	6,092,223

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LFST on your watchlist

Track score changes the day LifeStance Health Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LFST a good stock to buy?

13F Pro's AI-powered analysis of LifeStance Health Group, Inc. (LFST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFST are available on the LFST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LFST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LifeStance Health Group, Inc.'s investment landscape.